Gene Therapy: Four-Month Lag In Commercial Access Protects EMBARK Study, Sarepta Says

 
• By Sue Sutter
Mind the gap
The gap between accelerated approval of SRP-9001 and commercial access will be at least 8 weeks and more likely about 4 months, Sarepta says. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers